lxrx fda approval date：Lexicon Announces FDA Acceptance of New Drug Application
Lexicon Announces FDA Acceptance of New Drug Application
2022年7月27日—TheFDAassignedastandardreviewfortheNDAfilingwithaPrescriptionDrugUserFeeAct(PDUFA)targetactiondateinMay2023.。其他文章還包含有：「LexiconAnnouncesFDAApprovalofINPEFA™(sotagliflozin)」、「LexiconPharma」、「LexiconPharmaceuticalsInc.,LXRX」、「LexiconPharmaceuticalsReportsSecondQuarter2023...」、「Lexicon's(LXRX)HeartFailureDrugInpefa...」、「Lexicon's(LXRX)HeartFailureDru...
查看更多 離開網站
Lexicon Announces FDA Approval of INPEFA™ (sotagliflozin)
https://www.globenewswire.com
THE WOODLANDS, Texas, May 26, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the U.S. Food and Drug ...
Lexicon Pharma
https://seekingalpha.com
Lexicon's sotagliflozin, armed with strong data, will have a PDUFA in May 2023. Click to read more as I think this could boost up LXRX stock ...
Lexicon Pharmaceuticals Inc., LXRX
https://www.rttnews.com
Outcome Date, 05/26/2023 ; Outcome, FDA approved Sotagliflozin, under brand name INPEFA, for treatment of Heart Failure on May 26, 2023 ; Drug ...
Lexicon Pharmaceuticals Reports Second Quarter 2023 ...
https://finance.yahoo.com
On May 26, Lexicon announced that the U.S. Food and Drug Administration (FDA) approved INPEFA (sotagliflozin), a once-daily oral tablet to ...
Lexicon's (LXRX) Heart Failure Drug Inpefa ...
https://finance.yahoo.com
Lexicon's LXRX shares were up almost 18% on May 26, after market hours. The rise was due to the FDA approval of a broad label for Inpefa ...
Lexicon's (LXRX) Heart Failure Drug Inpefa Gets FDA Approval
https://www.nasdaq.com
The new drug application (NDA) for Inpefa was accepted by the food and drug administration (FDA) in June 2022. Lexicon expects to make Inpefa ...
LXRX stock on watch on FDA review of heart failure therapy ...
https://seekingalpha.com
Lexicon heart failure therapy undergoes FDA review again. Jul. 27, 2022 8:23 AM ETLexicon Pharmaceuticals, Inc. (LXRX)By: ...
May 27 PDUFA Date For Heart Failure Drug Looks Crucial
https://seekingalpha.com
Lexicon ought to find out whether its heart failure candidate sotagliflozin will be approved on May 27. Read why LXRX stock is a hold.
U.S. FDA approves Lexicon Pharma's drug for heart failure
https://www.reuters.com
May 26 (Reuters) - The U.S. Food and Drug Administration (FDA) has approved Lexicon Pharmaceuticals Inc's (LXRX.O) drug for a broad ...